<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04882007</url>
  </required_header>
  <id_info>
    <org_study_id>OSE-127-C201</org_study_id>
    <secondary_id>2020-001398-59</secondary_id>
    <nct_id>NCT04882007</nct_id>
  </id_info>
  <brief_title>Study of OSE-127 vs Placebo in Patients With Moderate to Severe Active Ulcerative Colitis</brief_title>
  <acronym>CoTikiS</acronym>
  <official_title>Randomized, Double-blind, Phase 2 Study to Evaluate the Efficacy and the Safety of OSE-127 Versus Placebo in Subjects With Moderate to Severe Active Ulcerative Colitis Who Have Failed or Are Intolerant to Previous Treatment(s)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OSE Immunotherapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OSE Immunotherapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group&#xD;
      study in patients with moderate to severe active ulcerative colitis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2, 2020</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>During the Double-blind phase all participants will be blinded to treatment assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in modified Mayo Score</measure>
    <time_frame>Baseline and Week 10</time_frame>
    <description>Change in modified Mayo Score between baseline and Week 10 clinical symptoms (stool frequency and rectal bleeding sub-scores) additionally to the endoscopic sub-score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Remission</measure>
    <time_frame>Week 10</time_frame>
    <description>Number and proportion of patients achieving clinical remission at Week 10, defined as a modified Mayo score of ≤ 2 points and with no individual sub-score of &gt; 1 point and a rectal bleeding at 0, therefore a stool frequency score of 0 or 1 and an endoscopic score of 0 or 1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical efficacy of OSE-127 vs placebo</measure>
    <time_frame>Week 10</time_frame>
    <description>Number and proportion of patients with a clinical response defined as a reduction in the modified Mayo score of ≥ 3 points and of ≥ 30% from baseline, with an accompanying decrease from baseline in the rectal bleeding sub-score of ≥ 1 point or an absolute rectal bleeding sub-score of ≤ 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of OSE-127 vs placebo on endoscopic remission</measure>
    <time_frame>Week 10</time_frame>
    <description>Number and proportion of patients with an endoscopic remission defined by an endoscopic Mayo sub-score =0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of OSE-127 vs placebo on endoscopic improvement</measure>
    <time_frame>Week 10</time_frame>
    <description>Number and proportion of patients with endoscopic response or improvement defined by an endoscopic subscore of Mayo ≤ 1 point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of OSE-127 vs placebo on endoscopic improvement</measure>
    <time_frame>Week 10</time_frame>
    <description>Mean change from baseline in the endoscopic activity measured by the Ulcerative Colitis Endoscopic Index of Severity (UCEIS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall safety and tolerability of OSE-127 in patients with moderate to severe UC</measure>
    <time_frame>Week 0 to Week 22 for patients not participating in the optional extension, and Week 0 to Week 50 for patients participating in the optional extension</time_frame>
    <description>Frequency and severity of reported treatment-emergent adverse events, serious adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>OSE-127 High dose induction phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OSE-127 Low dose induction phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 3 total infusions, weeks 0, 2, and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo induction phase</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal saline intravenous infusion 3 total infusions, weeks 0, 2, and 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OSE-127 High dose optional extension phase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OSE-127 mAb antagonist to CD127 receptor (or IL-7Rα) intravenous infusion 7 total infusions, weeks 10, 14, 18, 22, 26, 30, and 34</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OSE-127</intervention_name>
    <description>mAb antagonist to CD127 receptor (or IL-7Rα)</description>
    <arm_group_label>OSE-127 High dose induction phase</arm_group_label>
    <arm_group_label>OSE-127 High dose optional extension phase</arm_group_label>
    <arm_group_label>OSE-127 Low dose induction phase</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline</description>
    <arm_group_label>Placebo induction phase</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provision of signed and dated informed consent document indicating that the patient&#xD;
             has been informed of all the pertinent aspects of the trial prior to enrollment&#xD;
&#xD;
          2. Willingness and ability to comply with scheduled visits, treatment plans, laboratory&#xD;
             tests, and other study procedures&#xD;
&#xD;
          3. Willingness to refrain from live or attenuated vaccines during the study and for 12&#xD;
             weeks after last dose&#xD;
&#xD;
          4. Male or female 18 to 75 years of age, inclusive&#xD;
&#xD;
          5. Diagnosis of moderate to severe active UC made at least 3 months before the screening&#xD;
             visit. The diagnosis of UC must have been confirmed by endoscopy, with a minimal&#xD;
             extent of 15 cm from anal margin and histology (Moderate to severe active UC is&#xD;
             defined by a modified Mayo score between 4 and 9, inclusive. The modified Mayo score&#xD;
             is defined by the addition of the rectal bleeding subscore, the stool frequency&#xD;
             sub-score, and the endoscopic sub-score. Thus, to be included, a patient must have the&#xD;
             following:&#xD;
&#xD;
               1. a rectal bleeding score ≥ 1,&#xD;
&#xD;
               2. a stool frequency score ≥ 1 (sub-score calculated before bowel preparation), and&#xD;
&#xD;
               3. an endoscopic sub-score ≥ 2&#xD;
&#xD;
          6. No previous biologic therapy (i.e., TNF antagonists, vedolizumab or ustekinumab) and&#xD;
             prior or current UC documented medication history that includes at least 1 of the&#xD;
             following:&#xD;
&#xD;
               1. Corticosteroids&#xD;
&#xD;
               2. Immunosuppressive agents&#xD;
&#xD;
        OR&#xD;
&#xD;
        Previous or current biologic therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Stoma, proctocolectomy, or subtotal colectomy&#xD;
&#xD;
          2. Physician judgment that patient is likely to require any surgery for UC during the&#xD;
             study duration, or double-blind phase duration at least&#xD;
&#xD;
          3. Evidence of fulminant colitis, toxic megacolon, or perforation&#xD;
&#xD;
          4. Current or recent (within 4 weeks prior to screening) hospitalization for UC care&#xD;
             and/or treatment with IV steroids&#xD;
&#xD;
          5. The following laboratory results at screening:&#xD;
&#xD;
               1. Elevation at screening of aminotransferase (AST), alanine aminotransferase (ALT)&#xD;
                  &gt; 3 × the upper limit of normal (ULN) or total bilirubin &gt; 2 × ULN (unless due to&#xD;
                  Gilbert's disease) or evidence of chronic liver disease&#xD;
&#xD;
               2. Platelet count &lt; 100,000/mm3&#xD;
&#xD;
               3. Hemoglobin (Hgb) &lt; 8.5 g/dL&#xD;
&#xD;
               4. Neutrophils &lt; 1500/mm3&#xD;
&#xD;
               5. Lymphocytes &lt; 800/mm3&#xD;
&#xD;
               6. Absolute white blood cell (WBC) count &lt; 3000/mm3&#xD;
&#xD;
          6. Crohn's disease or indeterminate colitis or any other diagnosis not consisting with UC&#xD;
&#xD;
          7. History or evidence of incompletely resected colonic dysplasia or unconventional&#xD;
             lesion at risk of colonic adenocarcinoma&#xD;
&#xD;
          8. Stool culture or other examination positive for enteric pathogen, including&#xD;
             Clostridium difficile (C. diff) toxin. If positive, the patient should be treated and&#xD;
             rescreening is allowed.&#xD;
&#xD;
          9. Men or women with childbearing potential not willing to use adequate birth control&#xD;
             during the study. Adequate birth control includes surgical sterilization, intrauterine&#xD;
             device, oral contraceptive, contraceptive patch, long-acting injectable contraceptive,&#xD;
             partner's vasectomy, double-barrier method (condom, diaphragm with spermicide), or&#xD;
             abstinence during study and 30 days following the last follow-up visit. Women of&#xD;
             childbearing potential will enter the study after a negative pregnancy test.&#xD;
&#xD;
         10. Breastfeeding&#xD;
&#xD;
         11. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) from screening through&#xD;
             the end of the study&#xD;
&#xD;
         12. Use of topical steroids and/or topical 5-aminosalicylic acid preparations within 2&#xD;
             weeks before the screening visit (all such medications should be withdrawn at least 2&#xD;
             weeks prior to the screening visit)&#xD;
&#xD;
         13. Use of antidiarrheals within 2 weeks before the screening visit (all such medications&#xD;
             should be withdrawn at least 2 weeks prior to the screening visit)&#xD;
&#xD;
         14. Treatment with azathioprine, 6-MP, methotrexate (MTX), cyclosporin, tacrolimus,&#xD;
             sirolimus, leflunomide and/or mycophenolate mofetil within 4 weeks before the&#xD;
             screening visit (all such medications should be withdrawn at least 4 weeks prior to&#xD;
             the screening visit)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frederique Corallo, MD</last_name>
    <role>Study Director</role>
    <affiliation>OSE Immunotherapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Caroline Chevalier</last_name>
    <phone>+33 630 842 002</phone>
    <email>caroline.chevalier@ose-immuno.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brest Regional Hospital</name>
      <address>
        <city>Brest</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gomel Regional Clinical Hospital</name>
      <address>
        <city>Gomel</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Grodno University Hospital</name>
      <address>
        <city>Grodno</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>City Clinical Emergency Hospital</name>
      <address>
        <city>Minsk</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vitebsk Regional Clinical Hospital</name>
      <address>
        <city>Vitebsk</city>
        <country>Belarus</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UZ Leuven - Department of Gastroenterology and Hepatology</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Groupe Santé CHC - Clinique du Mont Légia</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Medconsult Pleven - OOD</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Medconsult Pleven</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Acibadem City Clinic University Multiprofile Hospital for Active Treatment - EOOD, Clinic of Gastroenterology</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Asklepion - Researches in humane medicine (EOOD)</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Asklepion</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Hera EOOD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Hera</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UMHAT Tsaritsa Yoanna - ISUL - EAD</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical center VIP Clinic - OOD</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center VIP Clinic</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University Hospital Center Split</name>
      <address>
        <city>Split</city>
        <country>Croatia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>EVEX Hospitals JSC</name>
      <address>
        <city>Kutaisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>West Regional Center of Modern Medical Technologies Ltd</name>
      <address>
        <city>Kutaisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Institute of Clinical Cardiology</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Israel-Georgia Medical Research Clinic Helsicore Ltd</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JSC Clinic Jerarsi</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Multiprofile Clinic Consilium Medulla Ltd</name>
      <address>
        <city>Tbilisi</city>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinexpert SMO</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>II. Sz. Belgyogyaszati Klinika, Semmelweis Egyetem</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>II. Sz Belgyogyasztai Intezet, Gasztroenterologia Debreceni Egyetem</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Polana-D</name>
      <address>
        <city>Daugavpils</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Liepāja Regional Hospital</name>
      <address>
        <city>Liepāja</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Digestive Diseases Centre GASTRO</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pauls Stradins Clinical University Hospital</name>
      <address>
        <city>Riga</city>
        <country>Latvia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Opieki Zdrowotnej Orkan-med</name>
      <address>
        <city>Ksawerów</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medicome Sp. z o.o.</name>
      <address>
        <city>Oświęcim</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Medyk</name>
      <address>
        <city>Rzeszów</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>WIP Warsaw IBD Point Profesor Kierkus</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Melita Medical</name>
      <address>
        <city>Wrocław</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne Med-Gastr</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oddział Kliniczny Gastroenterologii Ogólnej i Onkologicznej</name>
      <address>
        <city>Łódź</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ekaterinburg City Clinical Hospital No. 14</name>
      <address>
        <city>Ekaterinburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prof. S.V. Ochapovskiy Regional Clinical Hospital No.1</name>
      <address>
        <city>Krasnodar</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ryzhikh State Coloproctology Research Center</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>LLC Novosibirskiy Gastrocenter</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center Healthy Family LLC</name>
      <address>
        <city>Novosibirsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of the Stavropol Region - Pyatigorsk Oncology Dispensary</name>
      <address>
        <city>Pyatigorsk</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Saratov State Medical University</name>
      <address>
        <city>Saratov</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>301 Fairfield Medical Suite</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk I.I. Mechnikov Regional Clinical Hospital - Dnipropetrovsk Regional Council</name>
      <address>
        <city>Dnipro</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Prof. O.O. Salimov City Clinical Hospital #2 - Kharkiv City Council</name>
      <address>
        <city>Kharkiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kryvyi Rih City Clinical Hospital #2</name>
      <address>
        <city>Kryvyi Rih</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Kyiv Regional Clinical Hospital - Kyiv Regional Council</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical Center OK!Clinic+ of International Institute of Clinical Studies LLC</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ternopil University Hospital - Ternopil Regional Council</name>
      <address>
        <city>Ternopil</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Andrii Novak Transcarpathian Regional Clinical Hospital</name>
      <address>
        <city>Uzhhorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Municipal Institution City Clinical Hospital #6 - Therapeutic Department</name>
      <address>
        <city>Zaporizhzhya</city>
        <country>Ukraine</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Belarus</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Georgia</country>
    <country>Hungary</country>
    <country>Latvia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>May 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 11, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ulcerative colitis</keyword>
  <keyword>inflammatory bowel diseases</keyword>
  <keyword>Auto-Immune Diseases</keyword>
  <keyword>CD127/IL-7Rα Antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

